BACKGROUND: Standard-dose HSV-2 suppressive therapy (acyclovir 400 mg twice daily) reduces plasma HIV-1 levels by 0.25-0.50 log(10) copies/mL. It is not known if higher doses might further suppress HIV-1 levels. METHODS:We enrolled 32 HIV-1/HSV-2 dually infected Kenyan individuals who were not on antiretroviral therapy (ART) into a randomized, crossover trial of 2 dosing regimens of HSV-2 suppression: valacyclovir 1.5 g vs acyclovir 400 mg, both twice daily for 12 weeks, then a 2-week washout, and then the alternative for 12 weeks. Weekly plasma HIV-1 RNA quantity was measured (ClinicalTrials.gov number NCT01026454). RESULTS:Mean plasma HIV-1 levels were significantly lower on valacyclovir compared with acyclovir: 2.94 vs 3.56 log(10) copies/mL, an average difference of 0.62 log(10) copies/mL (95% confidence interval [CI]: -0.68, -0.55; P < .001), a 76% decrease. Valacyclovir resulted in a 1.23 log(10) copies/mL decrease compared with baseline HIV-1 levels without HSV-2 suppression. Adherence was similar (99.4% of dispensed study tablets taken), and high-dose valacyclovir was well tolerated. CONCLUSIONS: High-dose valacyclovir reduced plasma HIV-1 viral levels by 0.62 log(10) copies/mL compared with standard-dose acyclovir. The potential for higher-dose HSV-2 suppressive therapy to slow HIV-1 disease progression and reduce HIV-1 infectiousness among HIV-1/HSV-2 coinfected persons not yet eligible for ART warrants further evaluation.
RCT Entities:
BACKGROUND: Standard-dose HSV-2 suppressive therapy (acyclovir 400 mg twice daily) reduces plasma HIV-1 levels by 0.25-0.50 log(10) copies/mL. It is not known if higher doses might further suppress HIV-1 levels. METHODS: We enrolled 32 HIV-1/HSV-2 dually infected Kenyan individuals who were not on antiretroviral therapy (ART) into a randomized, crossover trial of 2 dosing regimens of HSV-2 suppression: valacyclovir 1.5 g vs acyclovir 400 mg, both twice daily for 12 weeks, then a 2-week washout, and then the alternative for 12 weeks. Weekly plasma HIV-1 RNA quantity was measured (ClinicalTrials.gov number NCT01026454). RESULTS: Mean plasma HIV-1 levels were significantly lower on valacyclovir compared with acyclovir: 2.94 vs 3.56 log(10) copies/mL, an average difference of 0.62 log(10) copies/mL (95% confidence interval [CI]: -0.68, -0.55; P < .001), a 76% decrease. Valacyclovir resulted in a 1.23 log(10) copies/mL decrease compared with baseline HIV-1 levels without HSV-2 suppression. Adherence was similar (99.4% of dispensed study tablets taken), and high-dose valacyclovir was well tolerated. CONCLUSIONS: High-dose valacyclovir reduced plasma HIV-1 viral levels by 0.62 log(10) copies/mL compared with standard-dose acyclovir. The potential for higher-dose HSV-2 suppressive therapy to slow HIV-1 disease progression and reduce HIV-1 infectiousness among HIV-1/HSV-2 coinfectedpersons not yet eligible for ART warrants further evaluation.
Authors: Kelika A Konda; Jeffrey D Klausner; Andres G Lescano; Segundo Leon; Franca R Jones; Jose Pajuelo; Carlos F Caceres; Thomas J Coates Journal: Sex Transm Dis Date: 2005-09 Impact factor: 2.830
Authors: E L Brown; A Wald; J P Hughes; R A Morrow; E Krantz; K Mayer; S Buchbinder; B Koblin; C Celum Journal: Am J Epidemiol Date: 2006-08-08 Impact factor: 4.897
Authors: Anuradha Rebbapragada; Charles Wachihi; Christopher Pettengell; Sherzana Sunderji; Sanja Huibner; Walter Jaoko; Blake Ball; Keith Fowke; Tony Mazzulli; Francis A Plummer; Rupert Kaul Journal: AIDS Date: 2007-03-12 Impact factor: 4.177
Authors: Ludo Lavreys; Jared M Baeten; Varsha Chohan; R Scott McClelland; Wisal M Hassan; Barbra A Richardson; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh Journal: Clin Infect Dis Date: 2006-03-27 Impact factor: 9.079
Authors: S Weller; M R Blum; M Doucette; T Burnette; D M Cederberg; P de Miranda; M L Smiley Journal: Clin Pharmacol Ther Date: 1993-12 Impact factor: 6.875
Authors: Richard A Zuckerman; Aldo Lucchetti; William L H Whittington; Jorge Sanchez; Robert W Coombs; Rosario Zuñiga; Amalia S Magaret; Anna Wald; Lawrence Corey; Connie Celum Journal: J Infect Dis Date: 2007-10-31 Impact factor: 5.226
Authors: Nicolas Nagot; Abdoulaye Ouédraogo; Vincent Foulongne; Issouf Konaté; Helen A Weiss; Laurence Vergne; Marie-Christine Defer; Didier Djagbaré; Anselme Sanon; Jean-Baptiste Andonaba; Pierre Becquart; Michel Segondy; Roselyne Vallo; Adrien Sawadogo; Philippe Van de Perre; Philippe Mayaud Journal: N Engl J Med Date: 2007-02-22 Impact factor: 91.245
Authors: Christophe Vanpouille; Andrea Lisco; Andrea Introini; Jean-Charles Grivel; Arshi Munawwar; Melanie Merbah; Raymond F Schinazi; Marco Derudas; Christopher McGuigan; Jan Balzarini; Leonid Margolis Journal: Antimicrob Agents Chemother Date: 2012-02-06 Impact factor: 5.191
Authors: Steven J Reynolds; Fred Makumbi; Kevin Newell; Noah Kiwanuka; Paschal Ssebbowa; George Mondo; Iga Boaz; Maria J Wawer; Ronald H Gray; David Serwadda; Thomas C Quinn Journal: Lancet Infect Dis Date: 2012-03-19 Impact factor: 25.071
Authors: Christophe Vanpouille; Andrea Lisco; Jean-Charles Grivel; Leda C Bassit; Robert C Kauffman; Jorge Sanchez; Raymond F Schinazi; Michael M Lederman; Benigno Rodriguez; Leonid Margolis Journal: Clin Infect Dis Date: 2015-03-03 Impact factor: 9.079
Authors: Supriya D Mehta; Stephen Moses; Kawango Agot; Ian Maclean; Elijah Odoyo-June; Hong Li; Robert C Bailey Journal: J Infect Dis Date: 2013-07-30 Impact factor: 5.226
Authors: Kathryn Curran; Jared M Baeten; Thomas J Coates; Ann Kurth; Nelly R Mugo; Connie Celum Journal: Curr HIV/AIDS Rep Date: 2012-06 Impact factor: 5.071
Authors: Sten H Vermund; José A Tique; Holly M Cassell; Megan E Pask; Philip J Ciampa; Carolyn M Audet Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731